首页> 外文期刊>European journal of human genetics: EJHG >SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency.
【24h】

SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency.

机译:SUMF1突变影响甲酰甘氨酸生成酶的稳定性和活性,预测多种硫酸酯酶缺乏症的临床结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Multiple Sulfatase Deficiency (MSD) is caused by mutations in the sulfatase-modifying factor 1 gene encoding the formylglycine-generating enzyme (FGE). FGE post translationally activates all newly synthesized sulfatases by generating the catalytic residue formylglycine. Impaired FGE function leads to reduced sulfatase activities. Patients display combined clinical symptoms of single sulfatase deficiencies. For ten MSD patients, we determined the clinical phenotype, FGE expression, localization and stability, as well as residual FGE and sulfatase activities. A neonatal, very severe clinical phenotype resulted from a combination of two nonsense mutations leading to almost fully abrogated FGE activity, highly unstable FGE protein and nearly undetectable sulfatase activities. A late infantile mild phenotype resulted from FGE G263V leading to unstable protein but high residual FGE activity. Other missense mutations resulted in a late infantile severe phenotype because of unstable protein with low residual FGE activity. Patients with identical mutations displayed comparable clinical phenotypes. These data confirm the hypothesis that the phenotypic outcome in MSD depends on both residual FGE activity as well as protein stability. Predicting the clinical course in case of molecularly characterized mutations seems feasible, which will be helpful for genetic counseling and developing therapeutic strategies aiming at enhancement of FGE.
机译:多种硫酸酯酶缺乏症(MSD)是由编码甲酰甘氨酸生成酶(FGE)的硫酸酯酶修饰因子1基因突变引起的。 FGE通过产生催化残基甲酰基甘氨酸翻译后活化所有新合成的硫酸酯酶。 FGE功能受损会导致硫酸酯酶活性降低。患者表现出单一硫酸酯酶缺乏症的综合临床症状。对于10名MSD患者,我们确定了临床表型,FGE表达,定位和稳定性,以及残留的FGE和硫酸酯酶活性。新生儿非常严重的临床表型是由两个无意义的突变共同导致的,导致几乎完全废除的FGE活性,高度不稳定的FGE蛋白和几乎不可检测的硫酸酯酶活性。 FGE G263V导致晚期婴儿轻度表型,导致蛋白质不稳定,但剩余FGE活性较高。其他错义突变导致晚期婴儿严重表型,因为不稳定的蛋白质具有较低的残留FGE活性。具有相同突变的患者表现出可比的临床表型。这些数据证实了以下假设:MSD中的表型结果取决于残留的FGE活性以及蛋白质稳定性。在分子特征突变的情况下预测临床过程似乎是可行的,这将有助于遗传咨询和开发旨在增强FGE的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号